Bobban Subhadra, MS, PhD.

Co-Founder & CEO

Experienced technology entrepreneur. More than 10 years of experience in the biotechnology industry, with a focus in drug discovery, bio-process development. Developed and commercialized numerous patented technologies and products for biochemical, biofuel and pharmaceutical companies.

Paul Carney, MD.

Co-Founder, Scientific & Medical Advisor

Nationally recognized clinician-scientist/epilepsy expert. Over $25M in federal funding (NIH, NSF, DOD). Board-certified pediatric neurologist. Over 400 peer-review papers, patients, and other works on epilepsy drug and device discovery. 10 U.S. patents and has authored several peer-reviewed publications, books and book chapters in epilepsy with a primary focus on novel drug discovery, biomarkers, and nanotechnology and gene therapy.

Christopher Anderson, M.S., Ph.D

Manager, Research & Clinical Operations

Dr. Christopher Anderson is an expert medical researcher with experience in bioengineering practices, data analysis, drug development, and project management within the Pharmaceutical and Medical industries. Dr. Anderson has worked in parallel as a Clinical Coordinator and Investigator on a number of cannabinoid focused projects, overseeing the initiation and completion of multiple clinical trials for industry sponsors, academic institutions, and federal grant agencies. Most recently, Dr. Anderson successfully coordinated a two-year research study supported by the Florida Department of Health for evaluating the safety and efficacy of Cannabidiol (CBD) treatment for children with intractable generalized epilepsy. As a former Research Professor, he collaborated and coordinated pre-clinical and clinical research studies focused on the treatment potential and pharmacology of new drugs for childhood neurology. Dr. Anderson received his Masters and Doctorate in Biomedical Engineering at the University of Florida.

BOARD OF
DIRECTORS

🏥 Bobban Subhadra
🏥 Paul Carney
🏥 John Allen